The DOI matches its Crossref record.
Polatuzumab Vedotin: First Global Approval
Open accessAbstract
Polatuzumab vedotin (polatuzumab vedotin-piiq; Polivy™) is an antibody-drug conjugate comprising a monoclonal antibody against CD79b (a B cell receptor component) covalently conjugated to the anti-mitotic cytotoxic agent monomethyl auristatin (MMAE) via a cleavable linker. After binding to CD79b on the B-cell surface, polatuzumab vedotin is internalized and the linker is cleaved, releasing MMAE into the cell, where it inhibits division and induces apoptosis. Polatuzumab vedotin is being developed by Genentech (a subsidiary of Roche) for the treatment of haematological malignancies. In June 2019, the US FDA granted accelerated approval to polatuzumab vedotin, in combination with bendamustine plus rituximab, for the treatment of adults with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) who have received at least two prior therapies. Use of the compound in combination with bendamustine plus rituximab is also under regulatory review for relapsed/refractory DLBCL in the EU and is in ongoing phase 1b/2 development in this setting or relapsed/refractory follicular lymphoma (FL) in several countries. Various other polatuzumab vedotin combination therapy regimens are also in phase 1b/2 development for relapsed/refractory non-Hodgkin lymphoma (NHL) [including DLBCL and FL] or in phase 2 or 3 development for previously untreated DLBCL, while polatuzumab vedotin monotherapy has been in phase 1 development for relapsed/refractory B-cell NHL in Japan. This article summarizes the milestones in the development of polatuzumab vedotin leading to this first approval for its use in combination with bendamustine plus rituximab for relapsed/refractory DLBCL.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Antibody drug conjugate: the “biological missile” for targeted cancer therapy
Fu, Z., Li, S., Han, S., Shi, C., & Zhang, Y. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00947-7 · Cited by 1,643
Site-selective modification strategies in antibody–drug conjugates
Walsh, S. J., Bargh, J. D., Dannheim, F. M., Hanby, A. R., Seki, H., Counsell, A. J., Ou, X., Fowler, E., Ashman, N., Takada, Y., et al. (2021) · Chemical Society Reviews · doi:10.1039/d0cs00310g · Cited by 461
Emerging new therapeutic antibody derivatives for cancer treatment
Jin, S., Sun, Y., Liang, X., Gu, X., Ning, J., Xu, Y., Chen, S., & Pan, L. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00868-x · Cited by 459
Mechanisms of ADC Toxicity and Strategies to Increase ADC Tolerability
Nguyen, T. D., Bordeau, B. M., & Balthasar, J. P. (2023) · Cancers · doi:10.3390/cancers15030713 · Cited by 441
Antibody–Drug Conjugates (ADCs): current and future biopharmaceuticals
Wang, R., Hu, B., Pan, Z., Mo, C., Zhao, X., Liu, G., Hou, P., Cui, Q., Xu, Z., Wang, W., et al. (2025) · Journal of Hematology & Oncology · doi:10.1186/s13045-025-01704-3 · Cited by 285
Metadata
- Authors
- Deeks, E. D.
- Venue
- Drugs
- Published
- 2019-07-27
- Volume
- 79
- Issue
- 13
- Pages
- 1467-1475
- ISSN
- 0012-6667 (ISSN-L)
- 1179-1950
- OpenAlex
- W2965572865
- Cited by
- 221
- References
- 0
- FWCI
- 15.96
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Polatuzumab Vedotin: First Global Approval. https://app.cochat.ai/papers/10.1007/s40265-019-01175-0
- The paper
- Deeks, E. D. (2019). Polatuzumab Vedotin: First Global Approval. Drugs. https://doi.org/10.1007/s40265-019-01175-0
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.